Sistemsko zdravljenje napredovalega medularnega karcinoma ščitnice

Show document
A+ | A- | | SLO | ENG

Title:	Sistemsko zdravljenje napredovalega medularnega karcinoma ščitnice
Authors:	ID Grašič-Kuhar, Cvetka (Author)
Files:	PDF - Presentation file, download (430,68 KB) MD5: D3D222F998BD9119C1AA9BD867F6F79B PID: 20.500.12556/dirros/a4bf4afa-1f75-456b-b4f6-a49b01dc2da9
Language:	Slovenian
Typology:	1.02 - Review Article
Organization:	OI - Institute of Oncology
Abstract:	Medularni karcinom ščitnice nastane iz nevroendokrinih celic ščitnice, ki izločajo kalcitonin. Kalcitonin je specifičen marker medularnega raka ščitnice. Pri lokalno napredovalem ali metastaskem medularnem raku ščitnice ob simptomtskem progresu prihaja v poštev zdravljenje s tirozin kinaznimi inhibitorji. Registrirani substanci sta vandetanib in cabozantinib, učinkoviti pa sta tudi sorafenib in sunitinib. Izbira zdravljenja je individualizirana glede na breme bolezni in spremljajoče bolezni. Zelo pomembno je tudi podporno (na simptome usmerjeno) zdravljenje.
Keywords:	medularni karcinom ščitnice, rak ščitnice, sistemsko zdravljenje, napredovali rak
Publication status:	Published
Publication version:	Version of Record
Year of publishing:	2016
Number of pages:	str. 4-6
Numbering:	Letn. 20, št. 1
PID:	20.500.12556/DiRROS-8144
UDC:	616.4
ISSN on article:	1408-1741
COBISS.SI-ID:	2415739
Copyright:	by Authors
Publication date in DiRROS:	03.01.2018
Views:	3958
Downloads:	1036
Metadata:
:	Copy citation

Share:

Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

License:	CC BY 4.0, Creative Commons Attribution 4.0 International

Link:	http://creativecommons.org/licenses/by/4.0/
Description:	This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:	03.01.2018

Language:	English
Title:	Systemic Treatment of Advanced Medullary Thyroid Carcinoma
Abstract:	Medullary thyroid carcinoma originates from neuroendocrine cells of the thyroid which secrete calcitonin. Calcitonin is a specific marker for medullary thyroid cancer. Therapy with tyrosine kinase inhibitors can be applied to treat locally advanced or metastatic medullary thyroid cancer with progressing symptoms. Registered substances used are vandetanib and cabozantinib, and sorafenib and sunitinib are also effective. Treatment is determined individually based on the burden of the cancer and secondary diseases. Supportive treatment (targeted at the symptoms) is also very important.
Keywords:	systemic treatment, medullary thyroid carcinoma, thyroid cancer